{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"title":"Disease Control - Yes"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}],"title":"Disease Control - No"}],"title":"6 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Disease Control - Yes"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"title":"Disease Control - No"}],"title":"12 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Disease Control - Yes"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"title":"Disease Control - No"}],"title":"24 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Disease Control - Yes"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"title":"Disease Control - No"}],"title":"36 Weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Participants were defined as having disease control at a specific time point if they had an evaluation of complete response (CR) or partial response (PR) at the time point (with a window of +/- 7 days) or had an evaluation of stable disease (SD), PR or CR at any point from the time point minus 7 days or later.","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6, 12, 24 and 36 weeks post first infusion (Part 1)","title":"Part 1: Number of Participants Who Experienced Disease Control","type":"SECONDARY","unitOfMeasure":"Participants"}